Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

Angendohr C, Weigel C, Kunstein A, Joerdens M, Goetze T, Al-Batran SE, Zäpf B, Gonzalez-Carmona M, Sahin C, Berres ML, Foerster F, Ben Khaled N, Koch C, Kandulski A, Wege H, Trebicka J, Jochheim LS, Dill MT, Springfeld C, Daum S, Treese C, Ehmer U, Luedde T, Bode J, Roderburg C

Open source

DOI: 10.1080/14796694.2026.2748246
Published: 2026 Oct 20
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2748246,
  title = {Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).},
  author = {Angendohr C and Weigel C and Kunstein A and Joerdens M and Goetze T and Al-Batran SE and Zäpf B and Gonzalez-Carmona M and Sahin C and Berres ML and Foerster F and Ben Khaled N and Koch C and Kandulski A and Wege H and Trebicka J and Jochheim LS and Dill MT and Springfeld C and Daum S and Treese C and Ehmer U and Luedde T and Bode J and Roderburg C},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2748246},
  url = {https://doi.org/10.1080/14796694.2026.2748246}
}

RIS

TY  - JOUR
TI  - Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).
AU  - Angendohr C
AU  - Weigel C
AU  - Kunstein A
AU  - Joerdens M
AU  - Goetze T
AU  - Al-Batran SE
AU  - Zäpf B
AU  - Gonzalez-Carmona M
AU  - Sahin C
AU  - Berres ML
AU  - Foerster F
AU  - Ben Khaled N
AU  - Koch C
AU  - Kandulski A
AU  - Wege H
AU  - Trebicka J
AU  - Jochheim LS
AU  - Dill MT
AU  - Springfeld C
AU  - Daum S
AU  - Treese C
AU  - Ehmer U
AU  - Luedde T
AU  - Bode J
AU  - Roderburg C
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2748246
UR  - https://doi.org/10.1080/14796694.2026.2748246
ER  -

APA

C, A., C, W., A, K., M, J., T, G., SE, A., B, Z., M, G., C, S., ML, B., F, F., N, B. K., C, K., A, K., H, W., J, T., LS, J., MT, D., C, S., S, D., C, T., U, E., T, L., J, B., & C, R. (2026). Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2748246

Source records

pubmed · retrieved 2026-11-10T13:57:59.975Z
europe-pmc · retrieved 2026-11-10T13:57:59.979Z